ArticleScientific reports2026
Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Molecular testing can refine the prediction of cancer recurrence. We sought to compare patterns of gene expression in patients with and without recurrence of well-differentiated thyroid cancer to identify pathways associated with recurrence and develop a predictive model based on gene expression. RNA was extracted and sequenced from archival tumor samples of patients well-differentiated thyroid cancer with (n = 8) and without (n = 8) recurrence, all of whom appear clinically at high risk for recurrence. A predictive model was developed using machine learning (ML) with the Thyroid Carcinoma TCGA PanCancer Atlas dataset and externally validated using archival samples. RNA-seq analysis from archival patient samples demonstrated gene expression patterns with striking sex-dependent differences. In tumors from female patients, the TNFα pathway was activated whereas tumors from males showed inhibition of TNFα and estradiol pathways, with findings externally validated through analysis of TCGA data. A prediction model based on TCGA data in female patients was developed that demonstrated an AUC of 0.88 in an external validation cohort for predicting recurrence, providing prognostic information that improves predictions beyond standard clinical parameters. Sex-dependent differences, specifically in TNFα and estrogen response pathways, in thyroid cancer recurrence have important implications for prognosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.